Inventiva (NASDAQ:IVA) Stock Price Down 6% – Should You Sell?

Inventiva S.A. (NASDAQ:IVA)’s share price was down 6% during mid-day trading on Monday . The company traded as low as $2.15 and last traded at $2.21. Approximately 9,217 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 70,537 shares. The stock had previously closed at $2.35.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on IVA shares. HC Wainwright reduced their price objective on Inventiva from $14.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, October 15th. UBS Group began coverage on shares of Inventiva in a research report on Tuesday, November 12th. They issued a “neutral” rating and a $3.00 price target on the stock. Finally, Stifel Nicolaus decreased their price target on shares of Inventiva from $20.00 to $17.00 and set a “buy” rating for the company in a report on Friday, November 22nd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $13.25.

Inventiva Stock Down 6.0 %

The stock has a 50 day moving average price of $2.62 and a 200 day moving average price of $2.49.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.